20200056 - D'Amato Gina
-
Investigator:
Gina D'Amato
Email
Coordinator: Nailet Real Bestard
+1 (305) 2438173
IRB: 20200056
SDG: Bone and Soft Tissue Cancers
Disease Site(s): Anus,Bladder,Bones and Joints,Breast,Cervix Uteri,Colon,Esophagus,Kidney,Lip, Oral Cavity and Pharynx,Liver,Lung,Melanoma, skin,Other Digestive Organ,Other Urinary,Ovary,Prostate,Rectum,Small Intestine,Soft Tissue,Stomach,Thyroid
Sponsor: DECIPHERA
Enrolling Sites:
Sylvester
Title: A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor
Eligibility Criteria - NCT03069469 *This information has been extracted from " www.clinicaltrials.gov"
MATCH - Huang, Marilyn
-
Investigator:
Marilyn Huang
Email
Coordinator: Carolina Troche
+1 (305) 2431481
IRB: 20150671
SDG: Gynecologic Cancer
Disease Site(s): Cervix Uteri,Colon,Corpus Uteri,Kaposis sarcoma,Kidney,Larynx,Liver,Multiple Myeloma,Non-Hodgkin Lymphoma,Other Female Genital,Ovary,Pancreas,Prostate,Soft Tissue
Sponsor: ECOG
Enrolling Sites:
Coral Springs
Deerfield
Gables
Hollywood
Kendall
Plantation
SylvesterTitle: Molecular Analysis for Therapy Choice (MATCH)
Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"
AL3818-US-002 - Huang, Marilyn
-
Investigator:
Marilyn Huang
Email
Coordinator:
IRB: 20170218
SDG: Gynecologic Cancer
Disease Site(s): Cervix Uteri,Corpus Uteri,Ovary
Sponsor: ADVENCHEN LABORATORIES
Enrolling Sites:
Deerfield
Gables
Plantation
SylvesterTitle: AL3818-US-002: A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects with Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma
Eligibility Criteria - NCT02584478 *This information has been extracted from " www.clinicaltrials.gov"
20170846 - Huang Marilyn
-
Investigator:
Marilyn Huang
Email
Coordinator:
IRB: 20170846
SDG: Gynecologic Cancer
Disease Site(s): Cervix Uteri
Sponsor: SCCC
Enrolling Sites:
Deerfield
Gables
Plantation
SylvesterTitle: Phase II Single Arm Study of Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients with Recurrent, Persistent, or Metastatic Cervical Cancer
Eligibility Criteria - NCT03367871 *This information has been extracted from " www.clinicaltrials.gov"
20190887 - Huang Marilyn
-
Investigator:
Marilyn Huang
Email
Coordinator: Violeta Milic
305-243-5181
IRB: 20190887
SDG: Gynecologic Cancer
Disease Site(s): Lung,Ovary
Sponsor: MER
Enrolling Sites:
Sylvester
Title: A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b
Eligibility Criteria - NCT03319628 *This information has been extracted from " www.clinicaltrials.gov"
20200931 - Huang Marilyn
-
Investigator:
Marilyn Huang
Email
Coordinator: Violeta Milic
305-243-5181
IRB: 20200931
SDG: Gynecologic Cancer
Disease Site(s): Corpus Uteri
Sponsor: GOG Foundation
Enrolling Sites:
Deerfield
Gables
Plantation
Sylvester
UMHTitle: A Phase II Study of Abemaciclib in Combination with Letrozole in Advanced, Recurrent or Metastatic Endometrioid Endometrial Cancer
Eligibility Criteria - NCT04393285 *This information has been extracted from " www.clinicaltrials.gov"
20211145 - Huang Marilyn
-
Investigator:
Marilyn Huang
Email
Coordinator: Isabel Fernandez
+1 (305) 2435486
IRB: 20211145
SDG: Gynecologic Cancer
Disease Site(s): Cervix Uteri,Ovary
Sponsor: Seagen Inc
Enrolling Sites:
Sylvester
Title: A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
Eligibility Criteria - NCT04665921 *This information has been extracted from " www.clinicaltrials.gov"
CPI-006-001 - Merchan, Jaime
-
Investigator:
Jaime Merchan
Email
Coordinator: Rakhi Modak
+1 (305) 2437387
IRB: 20180279
SDG: Prostate, Bladder, and Kidney Cancers
Disease Site(s): Bladder,Bones and Joints,Cervix Uteri,Colon,Corpus Uteri,Kidney,Lip, Oral Cavity and Pharynx,Lung,Lymphoid Leukemia,Non-Hodgkin Lymphoma,Pancreas,Prostate,Rectum,Soft Tissue
Sponsor: CP
Enrolling Sites:
Sylvester
Title: CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CPI-006, As A Single Agent, In Combination WIith CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers
Eligibility Criteria - NCT03454451 *This information has been extracted from " www.clinicaltrials.gov"
RTX-240-01 - Merchan, Jaime
-
Investigator:
Jaime Merchan
Email
Coordinator: Isabel Fernandez
+1 (305) 2435486
IRB: 20200686
SDG: Prostate, Bladder, and Kidney Cancers
Disease Site(s): Multiple
Sponsor: Rubius Therapeutics
Enrolling Sites:
Sylvester
Title: PHASE 1/2 STUDY OF RTX-240 AS A MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB
Eligibility Criteria - NCT04372706 *This information has been extracted from " www.clinicaltrials.gov"
20200854 - Penedo Frank
-
Investigator:
Frank Penedo
Email
Coordinator:
IRB: 20200854
SDG: Population Sciences
Disease Site(s): Ovary
Sponsor: NCI
Enrolling Sites:
Gables
Kendall
SylvesterTitle: Living Well: A Web-Based Program to Improve Quality of Life in Rural and Urban Ovarian Cancer Survivors
Eligibility Criteria - NCT04533763 *This information has been extracted from " www.clinicaltrials.gov"
Tbio-6517-ITu-001 - Pimentel, Agustin
-
Investigator:
Agustin Pimentel
Email
Coordinator: Rakhi Modak
+1 (305) 2437387
IRB: 20200277
SDG: Colorectal Cancer
Disease Site(s): Multiple
Sponsor: TSB
Enrolling Sites:
Sylvester
Title: A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination with Pembrolizumab, in Patients with Advanced Solid Tumors
Eligibility Criteria - NCT04301011 *This information has been extracted from " www.clinicaltrials.gov"
20150600 - Schlumbrecht Matthew
-
Investigator:
Matthew Schlumbrecht
Email
Coordinator:
IRB: 20150600
SDG: Gynecologic Cancer
Disease Site(s): Ovary
Sponsor: NCI
Enrolling Sites:
Deerfield
Gables
Plantation
SylvesterTitle: Use of CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
Eligibility Criteria - NCT00539162 *This information has been extracted from " www.clinicaltrials.gov"
20201370 - Sinno Abdulrahman
-
Investigator:
Abdulrahman Sinno
Email
Coordinator:
IRB: 20201370
SDG: Gynecologic Cancer
Disease Site(s): Ovary
Sponsor: M.D. ANDERSON
Enrolling Sites:
Sylvester
Title: 2020-0165: Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE)
Eligibility Criteria - NCT04575935 *This information has been extracted from " www.clinicaltrials.gov"
SPN-00714 - Valdes, Frances
-
Investigator:
Frances Valdes
Email
Coordinator: Yanel Diaz Caro
3052438227
IRB: 20190673
SDG: Other
Disease Site(s): Breast,Colon,Esophagus,Kidney,Lung,Other Female Genital,Ovary,Stomach
Sponsor: MTEM
Enrolling Sites:
Sylvester
Title: A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors
Eligibility Criteria - NCT04029922 *This information has been extracted from " www.clinicaltrials.gov"